Request Free Sample ×
China Endoscopic Retrograde Cholangiopancreatography Market Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Endoscopic Retrograde Cholangiopancreatography Market

ID: MRFR/HC/49843-HCR
200 Pages
Vikita Thakur
April 2026

China Endoscopic Retrograde Cholangiopancreatography Market Research Report: Size, Share, Trend Analysis By Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Duct Stenting, Others), By End Users (Hospitals and amp; Clinics, Ambulatory Surgical Centers), By Applications (Bile Duct, Pancreas, Others) and By Product (Endoscopes, Imaging Devices, Energy Devices) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Endoscopic Retrograde Cholangiopancreatography Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

China Endoscopic Retrograde Cholangiopancreatography Market Summary

As per analysis, the China endoscopic retrograde-cholangiopancreatography market size was estimated at 171.29 USD Million in 2024. The China endoscopic retrograde-cholangiopancreatography market is projected to grow from 188.08 USD Million in 2025 to 479.12 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 9% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The China endoscopic retrograde-cholangiopancreatography market is poised for growth driven by technological advancements and increasing healthcare expenditure.

  • Technological advancements in endoscopic devices are enhancing procedural efficiency and patient outcomes.
  • The rising incidence of biliary disorders is driving demand for endoscopic retrograde-cholangiopancreatography procedures.
  • Training and education initiatives are becoming crucial for healthcare professionals to keep pace with evolving technologies.
  • Increasing healthcare expenditure and a growing aging population are significant drivers of market expansion.

Market Size & Forecast

2024 Market Size 171.29 (USD Million)
2035 Market Size 479.12 (USD Million)
CAGR (2025 - 2035) 9.8%

Major Players

Boston Scientific (US), Medtronic (US), Olympus Corporation (JP), Cook Medical (US), Fujifilm Holdings Corporation (JP), Conmed Corporation (US), Hoya Corporation (JP), B. Braun Melsungen AG (DE)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

China Endoscopic Retrograde Cholangiopancreatography Market Trends

The endoscopic retrograde-cholangiopancreatography market is currently experiencing notable growth, driven by advancements in medical technology and increasing demand for minimally invasive procedures. In China, the healthcare sector is evolving rapidly, with a focus on improving patient outcomes and enhancing diagnostic capabilities. This trend is reflected in the rising adoption of endoscopic techniques, which offer significant advantages over traditional surgical methods. Furthermore, the growing prevalence of biliary and pancreatic disorders necessitates effective diagnostic and therapeutic solutions, thereby propelling the market forward. As healthcare infrastructure continues to improve, the accessibility of endoscopic retrograde-cholangiopancreatography is likely to expand, catering to a larger patient population. In addition, the emphasis on training and education for healthcare professionals is crucial for the advancement of the endoscopic retrograde-cholangiopancreatography market. Enhanced training programs and workshops are being implemented to ensure that practitioners are well-versed in the latest techniques and technologies. This focus on skill development is expected to lead to better procedural outcomes and increased patient safety. Moreover, collaboration between medical institutions and technology providers is fostering innovation, resulting in the introduction of advanced endoscopic equipment and tools. Overall, the endoscopic retrograde-cholangiopancreatography market appears poised for sustained growth, driven by technological advancements and a commitment to improving healthcare delivery in China.

Technological Advancements

The endoscopic retrograde-cholangiopancreatography market is witnessing rapid technological innovations, including the development of high-definition imaging systems and advanced endoscopic tools. These enhancements improve diagnostic accuracy and procedural efficiency, making it easier for healthcare professionals to perform complex interventions.

Rising Incidence of Biliary Disorders

There is a growing prevalence of biliary and pancreatic diseases in China, which is driving demand for effective diagnostic and therapeutic solutions. This trend is likely to increase the utilization of endoscopic retrograde-cholangiopancreatography as a preferred method for managing these conditions.

Focus on Training and Education

The emphasis on training healthcare professionals in endoscopic techniques is becoming increasingly important. Enhanced educational programs are being established to ensure practitioners are equipped with the necessary skills, which may lead to improved patient outcomes and procedural success.

China Endoscopic Retrograde Cholangiopancreatography Market Drivers

Aging Population

China's aging population is a significant factor influencing the endoscopic retrograde-cholangiopancreatography market. With an increasing number of individuals aged 65 and above, the prevalence of biliary and pancreatic diseases is expected to rise. By 2025, it is estimated that over 300 million people in China will be aged 60 and older, leading to a higher demand for diagnostic and therapeutic procedures. This demographic shift necessitates the use of advanced medical technologies, including endoscopic retrograde-cholangiopancreatography, to address the complex health needs of older adults. As healthcare providers adapt to this demographic trend, the endoscopic retrograde-cholangiopancreatography market is poised for growth, driven by the need for effective management of age-related health issues.

Increasing Healthcare Expenditure

The rising healthcare expenditure in China is a pivotal driver for the endoscopic retrograde-cholangiopancreatography market. As the government allocates more funds towards healthcare, hospitals and clinics are increasingly investing in advanced medical technologies. In 2025, healthcare spending in China is projected to reach approximately $1 trillion, reflecting a growth rate of around 10% annually. This financial commitment enables healthcare facilities to acquire state-of-the-art endoscopic equipment, thereby enhancing diagnostic and therapeutic capabilities. Furthermore, the emphasis on improving healthcare infrastructure supports the adoption of endoscopic retrograde-cholangiopancreatography procedures, which are essential for diagnosing and treating biliary and pancreatic disorders. Consequently, the endoscopic retrograde-cholangiopancreatography market is likely to experience substantial growth as healthcare providers seek to offer high-quality services to patients.

Government Initiatives and Policies

Government initiatives and policies aimed at enhancing healthcare access and quality are crucial drivers for the endoscopic retrograde-cholangiopancreatography market. The Chinese government has implemented various reforms to improve healthcare services, including the Healthy China 2030 initiative, which emphasizes the importance of early diagnosis and treatment of diseases. These policies encourage the adoption of advanced medical technologies, including endoscopic retrograde-cholangiopancreatography, in hospitals and clinics. Additionally, the government is investing in training healthcare professionals to ensure they are equipped with the necessary skills to perform these procedures effectively. As a result, the endoscopic retrograde-cholangiopancreatography market is likely to benefit from increased utilization of these services, ultimately leading to better patient outcomes.

Rising Awareness of Biliary Disorders

The growing awareness of biliary disorders among the Chinese population is a notable driver for the endoscopic retrograde-cholangiopancreatography market. As public health campaigns and educational initiatives highlight the symptoms and risks associated with biliary diseases, more individuals are seeking medical attention. This heightened awareness is likely to lead to an increase in diagnostic procedures, including endoscopic retrograde-cholangiopancreatography, as patients become more proactive about their health. Furthermore, healthcare providers are responding to this trend by offering more comprehensive screening and diagnostic services. Consequently, the endoscopic retrograde-cholangiopancreatography market is expected to expand as the demand for these procedures rises in tandem with public awareness.

Technological Innovations in Medical Devices

Technological innovations in medical devices are transforming the landscape of the endoscopic retrograde-cholangiopancreatography market. Advances in imaging technologies, such as high-definition endoscopes and improved contrast agents, enhance the accuracy and effectiveness of procedures. In 2025, the market for endoscopic equipment in China is projected to grow at a CAGR of approximately 8%, driven by these innovations. Additionally, the integration of artificial intelligence and machine learning in diagnostic tools is likely to streamline the workflow and improve patient outcomes. As healthcare facilities adopt these cutting-edge technologies, the endoscopic retrograde-cholangiopancreatography market is expected to flourish, providing better diagnostic and therapeutic options for patients.

Market Segment Insights

By Procedure: Biliary Sphincterotomy (Largest) vs. Pancreatic Duct Stenting (Fastest-Growing)

In the China endoscopic retrograde-cholangiopancreatography market, Biliary Sphincterotomy holds the largest share, reflecting its established role in treating biliary obstructions and pancreatitis. In contrast, Biliary Stenting, Biliary Dilatation, and Others are significant, but they do not match the dominance of Biliary Sphincterotomy. Pancreatic Duct Stenting, while having a smaller market share, is gaining traction due to increasing awareness and advancements in minimally invasive techniques. The growth trends in this segment are fueled by a rising incidence of biliary disorders and a growing aging population, which is more susceptible to these issues. Innovations in endoscopic techniques and tools are also driving demand for procedures like Biliary Sphincterotomy and Pancreatic Duct Stenting, enabling more patients to benefit from these interventions. Furthermore, favorable reimbursement policies and improved healthcare infrastructure in China contribute positively to the growth of this segment.

Biliary Sphincterotomy (Dominant) vs. Pancreatic Duct Stenting (Emerging)

Biliary Sphincterotomy is characterized by its established presence as a critical procedure in managing biliary drainage and relieving obstructions, making it the dominant choice among physicians. Its efficacy and safety have made it a standard procedure in the China endoscopic retrograde-cholangiopancreatography market. On the other hand, Pancreatic Duct Stenting is emerging as an important alternative, providing options for patients with pancreatic duct strictures. The market recognition of Pancreatic Duct Stenting is growing, driven by technological advancements and a focus on patient-centered treatments. As awareness of its benefits continues to expand, its market share is expected to increase, positioning it as a notable contender in the landscape of endoscopic retrograde-cholangiopancreatography.

By End User: Hospitals & Clinics (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the China endoscopic retrograde-cholangiopancreatography market, Hospitals & Clinics dominate the end user segment, capturing a significant market share due to their extensive infrastructure and established reputation for providing comprehensive healthcare services. The preference for hospitals arises from their capability to manage complex cases and offer a wide range of diagnostic and therapeutic interventions. Conversely, Ambulatory Surgical Centers represent the fastest-growing segment, gaining traction for their efficiency, reduced waiting times, and cost-effectiveness, making them an appealing option for many patients seeking specialized care. The growth trends in this segment are strongly influenced by advancements in endoscopic techniques and increasing awareness of minimally invasive procedures. Hospital networks are expanding their services to include outpatient care, while Ambulatory Surgical Centers are rapidly adapting to cater to the rising demand for less invasive surgeries. The shift towards outpatient care is driven by patient preferences for shorter recovery times and lower healthcare costs, propelling the growth of Ambulatory Surgical Centers as an alternative to traditional hospital settings.

End User: Hospitals & Clinics (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals & Clinics are recognized as the dominant end user category in the market, primarily due to their comprehensive facilities and capability to handle a broad spectrum of medical needs, including complex endoscopic procedures. They offer a wide range of services under one roof, giving patients convenience and access to multidisciplinary teams of specialists. In contrast, Ambulatory Surgical Centers are emerging as a viable alternative, characterized by lower operational costs and quicker patient turnover. These centers focus on outpatient procedures, appealing to patients who prefer rapid processes and shorter recovery times. With the healthcare landscape's evolution, both segments are essential, catering to different patient needs and preferences within the endoscopic retrograde-cholangiopancreatography market.

By Application: Bile Duct (Largest) vs. Pancreas (Fastest-Growing)

In the China endoscopic retrograde-cholangiopancreatography market, the application segment is primarily divided into three categories: Bile Duct, Pancreas, and Others. Currently, the Bile Duct application holds the largest market share due to its extensive use in diagnosing and treating bile duct-related conditions. The Pancreas segment, while smaller, is rapidly gaining traction as new technologies and techniques drive its growth. Other applications also contribute to the overall market but do not significantly impact the leading segments. Growth trends in this segment are influenced by increasing awareness about endoscopic procedures and advancements in medical technologies that enhance procedural outcomes. The demand for effective treatment options for pancreatic and bile duct disorders is on the rise, prompting healthcare providers to adopt these methods extensively. Overall, the Bile Duct remains a dominant player, while innovations are expected to propel the Pancreas segment to new heights in the coming years.

Bile Duct (Dominant) vs. Pancreas (Emerging)

The Bile Duct application stands as the dominant force in the China endoscopic retrograde-cholangiopancreatography market, attributed to its broad application in managing cholangiocarcinomas and other bile duct obstructions. This segment benefits from well-established techniques and a strong preference among healthcare professionals, promoting its continued dominance. In contrast, the Pancreas application is emerging, driven by a growing demand for diagnostic and therapeutic procedures addressing pancreatic disorders. Advancements in technology are enhancing the efficiency of pancreas-related endoscopic procedures, leading to an upswing in adoption rates. As the medical community focuses on improving patient outcomes and minimizing invasiveness, both segments play critical roles, with Bile Duct leading, while Pancreas shows significant promise for future growth.

By Product: Endoscopes (Largest) vs. Endotherapy Devices (Fastest-Growing)

In the China endoscopic retrograde-cholangiopancreatography market, the segment values are led by Endoscopes, which hold the largest market share due to their extensive application in diagnostic and therapeutic procedures. Following Endoscopes, Endotherapy Devices have been gaining traction, showcasing a substantial growth pattern as they enable advanced treatment options. Other significant segments include Catheters, Stents, and Imaging Devices, each contributing to the overall market dynamics. The growth trends within this market segment are primarily driven by the rising prevalence of biliary disorders and the increasing adoption of minimally invasive procedures. Furthermore, advancements in technology, such as the introduction of smart devices and enhanced imaging techniques, are propelling the demand for Endotherapy Devices. This segment is expected to expand rapidly, supported by ongoing innovations and a growing emphasis on patient safety and comfort.

Endoscopes (Dominant) vs. Endotherapy Devices (Emerging)

Endoscopes have proven to be the dominant product in the China endoscopic retrograde-cholangiopancreatography market, primarily owing to their critical role in facilitating complex procedures. Their ability to provide real-time visuals of the biliary system makes them indispensable in diagnostics and therapeutic interventions. In contrast, Endotherapy Devices are emerging as key players, driven by technological advancements that have enhanced their effectiveness and safety. These devices, which encompass tools like balloons and stents, are increasingly preferred due to their minimally invasive nature. The synergy between these two segments showcases the market's versatility, as Endoscopes ensure accurate diagnosis, while Endotherapy Devices offer innovative treatment solutions.

Get more detailed insights about China Endoscopic Retrograde Cholangiopancreatography Market
Request Free Sample

Key Players and Competitive Insights

The endoscopic retrograde-cholangiopancreatography market in China is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for minimally invasive procedures. Key players such as Boston Scientific (US), Medtronic (US), and Olympus Corporation (JP) are strategically positioned to leverage innovation and expand their market presence. Boston Scientific (US) focuses on enhancing its product portfolio through continuous innovation, while Medtronic (US) emphasizes strategic partnerships to bolster its technological capabilities. Olympus Corporation (JP) is investing in digital transformation initiatives to improve operational efficiency and patient outcomes. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and responsiveness to market needs.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several key players holding significant market shares. This fragmentation allows for a diverse range of products and services, fostering competition among established firms and new entrants alike. The collective influence of these key players shapes market dynamics, as they strive to differentiate themselves through unique offerings and customer engagement strategies.

In October Boston Scientific (US) announced the launch of a new endoscopic retrograde-cholangiopancreatography system designed to improve procedural efficiency and patient safety. This strategic move is likely to enhance the company's competitive edge by addressing the growing demand for advanced medical technologies in China. The introduction of this system may also reflect Boston Scientific's commitment to innovation and its ability to respond to evolving market needs.

In September Medtronic (US) entered into a partnership with a leading Chinese healthcare provider to expand its reach in the endoscopic retrograde-cholangiopancreatography market. This collaboration is expected to facilitate the introduction of Medtronic's advanced technologies in local hospitals, thereby enhancing patient access to cutting-edge medical solutions. Such strategic alliances may prove crucial in navigating the complexities of the Chinese healthcare landscape and establishing a strong foothold in the region.

In August Olympus Corporation (JP) unveiled a new digital platform aimed at streamlining endoscopic procedures, including endoscopic retrograde-cholangiopancreatography. This initiative underscores Olympus's focus on digital transformation and its potential to improve operational efficiencies. By integrating advanced technologies into its offerings, Olympus may enhance the overall quality of care and patient outcomes, positioning itself as a leader in the market.

As of November current competitive trends indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in medical procedures. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve, with a greater emphasis on technological advancements and supply chain reliability rather than solely on price. This shift suggests that companies must prioritize innovation and adaptability to maintain their competitive edge in a rapidly changing market.

Key Companies in the China Endoscopic Retrograde Cholangiopancreatography Market include

Industry Developments

Recent developments in the China Endoscopic Retrograde Cholangiopancreatography Market (ERCP) Market reflect a growing emphasis on advanced technologies and patient care. Notable advancements include Fujifilm's launch of enhanced imaging technologies specifically tailored for ERCP procedures in June 2023, designed to improve diagnostic accuracy.

Johnson and Johnson has also expanded its product offerings in China, focusing on ERCP accessories and tools to enhance procedural efficiency, while GE Healthcare has made strides in integrating artificial intelligence capabilities into imaging modalities to elevate procedure outcomes.In terms of mergers and acquisitions, there has been increased activity, particularly with Olympus Corporation announcing an acquisition of a smaller medical device firm in China in August 2023 to bolster its ERCP product lines.

The market's valuation is anticipated to grow significantly, projected to reach USD 1.2 billion by 2026, driven primarily by rising healthcare expenditures and increasing prevalence of biliary diseases. Regulatory support from the National Medical Products Administration for innovative ERCP technologies has further fueled market momentum. Consequently, these developments position the China ERCP market as a rapidly evolving sector with substantial opportunities for existing players like Boston Scientific and Medtronic.

Future Outlook

China Endoscopic Retrograde Cholangiopancreatography Market Future Outlook

The Endoscopic Retrograde Cholangiopancreatography Market in China is projected to grow at a 9.8% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare investments.

New opportunities lie in:

  • Development of AI-assisted diagnostic tools for enhanced accuracy
  • Expansion of telemedicine platforms for remote consultations
  • Investment in training programs for specialized endoscopic technicians

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare demands.

Market Segmentation

China Endoscopic Retrograde Cholangiopancreatography Market Product Outlook

  • Endoscopes
  • Endotherapy Devices
  • Catheters
  • Stents
  • Balloons
  • Guiding Wires
  • Others
  • Imaging Devices
  • Energy Devices

China Endoscopic Retrograde Cholangiopancreatography Market End User Outlook

  • Hospitals & Clinics
  • Ambulatory Surgical Centers

China Endoscopic Retrograde Cholangiopancreatography Market Procedure Outlook

  • Biliary Sphincterotomy
  • Biliary Stenting
  • Biliary Dilatation
  • Pancreatic Duct Stenting
  • Others

China Endoscopic Retrograde Cholangiopancreatography Market Application Outlook

  • Bile Duct
  • Pancreas
  • Others

Report Scope

MARKET SIZE 2024 171.29(USD Million)
MARKET SIZE 2025 188.08(USD Million)
MARKET SIZE 2035 479.12(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 9.8% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Boston Scientific (US), Medtronic (US), Olympus Corporation (JP), Cook Medical (US), Fujifilm Holdings Corporation (JP), Conmed Corporation (US), Hoya Corporation (JP), B. Braun Melsungen AG (DE)
Segments Covered Procedure, End User, Application, Product
Key Market Opportunities Advancements in imaging technologies enhance diagnostic accuracy in the endoscopic retrograde-cholangiopancreatography market.
Key Market Dynamics Technological advancements and regulatory changes drive growth in the endoscopic retrograde-cholangiopancreatography market.
Countries Covered China
Author
Author
Author Profile
Vikita Thakur LinkedIn
Senior Research Analyst
She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.
Co-Author
Co-Author Profile
Garvit Vyas LinkedIn
Vice President - Operations
Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.
Get In Touch
Leave a Comment

FAQs

What was the market valuation of the endoscopic retrograde-cholangiopancreatography market in 2024?

<p>The market valuation was $171.29 Million in 2024.</p>

What is the projected market valuation for 2035?

<p>The projected market valuation for 2035 is $479.12 Million.</p>

What is the expected CAGR for the market during the forecast period 2025 - 2035?

<p>The expected CAGR for the market during the forecast period 2025 - 2035 is 9.8%.</p>

Which companies are considered key players in the market?

<p>Key players in the market include Boston Scientific, Medtronic, Olympus Corporation, Cook Medical, Fujifilm Holdings Corporation, Conmed Corporation, Hoya Corporation, and B. Braun Melsungen AG.</p>

What segment had the highest valuation in the procedure category?

<p>In the procedure category, Biliary Stenting had the highest valuation at $142.12 Million.</p>

How do hospitals and clinics compare to ambulatory surgical centers in terms of market valuation?

<p>Hospitals and clinics had a market valuation of $276.0 Million, significantly higher than the $203.12 Million for ambulatory surgical centers.</p>

What is the valuation range for the bile duct application segment?

<p>The valuation range for the bile duct application segment is from $85.0 Million to $239.0 Million.</p>

Which product segment is projected to have the highest valuation?

<p>The Endoscopes product segment is projected to have the highest valuation, ranging from $30.0 Million to $85.0 Million.</p>

What is the valuation for pancreatic duct stenting in the procedure segment?

<p>The valuation for pancreatic duct stenting in the procedure segment is between $24.87 Million and $69.12 Million.</p>

What does the market outlook suggest for the endoscopic retrograde-cholangiopancreatography market in China?

<p>The market outlook suggests robust growth, with a projected increase to $479.12 Million by 2035.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓
%>